Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry-Reference-Cited by-同舟云学术

Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry

Published:2004-12-15 Issue:11 Volume:78 Page:1676-1682
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Aull Meredith J.,Buell Joseph F.,Trofe Jennifer,First M Roy,Alloway Rita R.,Hanaway Michael J.,Wagoner Lynne,Gross Thomas G.,Beebe Thomas,Woodle E Steve

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference21 articles.

1. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.;Mihalov;Clin Transplant,1996

2. The changing pattern of posttransplant malignancies.;Penn;Transplant Proc,1991

3. Malignant tumors after heart transplantation.;Couetil;J Heart Transplant,1990

4. Eight-year results of cyclosporine-treated patients with cardiac transplants.;Grattan;J Thorac Cardiovasc Surg,1990

5. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.;Armitage;J Heart Lung Transplant,1991

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post‐Transplant Malignancy and Lymphoproliferative Diseases;Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease;2023-09-08

2. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria;HemaSphere;2021-09-06

3. Late-Onset Posttransplant Lymphoproliferative Disorder Results in Jejunal Stricture Managed with Endoscopic Dilation;Case Reports in Gastrointestinal Medicine;2021-08-03

4. PTLD After Heart Transplantation;Post-Transplant Lymphoproliferative Disorders;2021

5. Management of PTLD after SOT;Post-Transplant Lymphoproliferative Disorders;2021